---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-065674"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:28:05.908675+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Relmada Therapeutics updates corporate presentation; no material new information disclosed

## Summary
- Company filed updated corporate presentation as Exhibit 99.1 on August 10, 2023.
- Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders'.
- Filing does not include specific new financial results, guidance, or milestones.
- No material changes to corporate strategy or pipeline disclosed in the filing.

## SEC filing metadata
- accession: 0001213900-23-065674
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/0001213900-23-065674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/ea183245-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-065674
- JSON: https://secwatch.observer/filing/0001213900-23-065674.json
- Plain text: https://secwatch.observer/filing/0001213900-23-065674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.